These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
7. Can Chen M; Zhuang J; Fu Y; Guo S; Zang S; Ai S; Qiu X; Wang F; Guo H J Urol; 2021 Apr; 205(4):1082-1089. PubMed ID: 33207140 [TBL] [Abstract][Full Text] [Related]
8. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study. Domachevsky L; Bernstine H; Goldberg N; Nidam M; Catalano OA; Groshar D Eur Radiol; 2020 Jan; 30(1):328-336. PubMed ID: 31332559 [TBL] [Abstract][Full Text] [Related]
9. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284 [TBL] [Abstract][Full Text] [Related]
10. Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning. Gupta SK; Watson T; Denham J; Shakespeare TP; Rutherford N; McLeod N; Picton K; Ainsworth P; Bonaventura T; Martin JM Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):701-709. PubMed ID: 29280465 [TBL] [Abstract][Full Text] [Related]
11. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial. Joshi A; Roberts MJ; Perera M; Williams E; Rhee H; Pryor D; Lehman M; Heathcote P; Wood S; Coucher J; Gustafson S; Miles K; Vela I Clin Exp Metastasis; 2020 Aug; 37(4):551-560. PubMed ID: 32519046 [TBL] [Abstract][Full Text] [Related]
13. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970 [TBL] [Abstract][Full Text] [Related]
14. Detection and localisation of primary prostate cancer using Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602 [TBL] [Abstract][Full Text] [Related]
15. Prostate-Specific Membrane Antigen (PSMA) PET: A Counterpart to Prostate MRI. Chen C; Margolis DJ Semin Roentgenol; 2021 Oct; 56(4):376-383. PubMed ID: 34688340 [No Abstract] [Full Text] [Related]
16. Prostate imaging: Contribution of PET PSMA and MRI. Abecassis JP; Ghazzar N; Peyromaure M; Giraud P Cancer Radiother; 2020 Aug; 24(5):423-428. PubMed ID: 32620459 [TBL] [Abstract][Full Text] [Related]
17. 68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients. Sanli Y; Sanli O; Has Simsek D; Subramaniam RM Nucl Med Commun; 2018 Oct; 39(10):871-880. PubMed ID: 30124601 [TBL] [Abstract][Full Text] [Related]
18. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093 [TBL] [Abstract][Full Text] [Related]